4.7 Article

Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England

Journal

BRITISH JOURNAL OF CANCER
Volume 126, Issue 5, Pages 804-814

Publisher

SPRINGERNATURE
DOI: 10.1038/s41416-021-01509-4

Keywords

-

Categories

Funding

  1. British Association for the Study of the Liver
  2. BTG International Ltd.
  3. Bayer
  4. Sirtex
  5. Bristol-Myers-Squibb (BMS)

Ask authors/readers for more resources

The study identified clear disparities in HCC incidence, management, and survival across regions in England, with socioeconomic factors playing a role. Only a minority of patients received potentially curative treatment, and the proportion of emergency presentations varied. One-year survival rates also differed across regions.
Background Hepatocellular carcinoma (HCC) incidence, management and survival across England were examined to determine if geographical inequalities exist. Method 15,468 HCC cases diagnosed 2010-2016 were included. Age-standardised incidence rates, net survival and proportions receiving potentially curative treatment and presenting through each route to diagnosis adjusted for age at diagnosis, sex and area-based deprivation quintile, were calculated overall and by Cancer Alliance. Results HCC incidence rates increased in men from 6.2 per 100,000 in 2010 to 8.8 in 2016, and in women from 1.5 to 2.2. The highest incidence rates, found in parts of the North of England and London, were nearly double the lowest. The adjusted proportion presenting as an emergency ranged 27-41% across Cancer Alliances. Odds increased with increasing deprivation quintile and age. Only one in five patients received potentially curative treatment (range 15-28%) and odds decreased with increasing deprivation and age. One-year survival in 2013-2016 ranged 38-53%. Conclusion This population-based, nationwide analysis demonstrates clear differences in HCC incidence, management and survival across England. It highlights socioeconomic-associated variation and the need for improvement in early diagnosis and curative treatment of HCC. This research should assist policymakers, service providers and clinicians to identify regions where additional training, services and resources would be best directed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available